Biotech, Pharmaceutical & Medical Equipment Auctions & Asset Sales

Ongoing modernization within biotech, pharmaceutical, and medical operations results in surplus laboratory, production, and facility assets as research priorities shift, products reach end of life, and manufacturing footprints evolve. Heritage Global Partners has a long track record supporting asset dispositions within this sector for research laboratories, clinical operations, and regulated manufacturing facilities, including surplus laboratory equipment sales and complete facility liquidations, frequently spanning multiple operational sites.

Heritage Global Partners maintains exclusive master service agreements with Pfizer and Amgen for the disposition of surplus biotech and pharmaceutical assets. Sales in this category originate from research and development transitions, facility consolidations, and corporate restructuring, supporting buyers active in regulated scientific and healthcare environments.

Typical Assets Sold

Current Auctions

Past Auctions

PSS (Pre 2023)
Global Online Auction Featuring Quality Biotech and Pharmaceutical Lab Equipment From Multiple Global Sellers! Multiple Locations, US.

Starting: Sep 15th, 2022 7:00am PDT

Ending: Sep 16th, 2022 8:00am PDT

Immediately Accepting Bids
Silverback
Global Online Auction Featuring State of the Art BioPharma Lab Equipment Surplus To A Seattle Based Therapeutics Company! Seattle, WA.

Starting: Sep 13th, 2022 7:00am PDT

Ending: Sep 14th, 2022 9:00am PDT

Immediately Accepting Bids
Ardelyx
Global Online Auction Featuring Quality R&D and Manufacturing Equipment from a Bay Area Specialized Biopharma Company. Hayward, CA.

Starting: Sep 8th, 2022 7:00am PDT

Ending: Sep 9th, 2022 10:00am PDT

Immediately Accepting Bids
Viatris Morgantown
5th In A Series Of Major Auctions Featuring Solid Dose Processing, Packaging & Lab Equipment Formerly of Viatris’ Morgantown, WV Site!

Starting: Sep 6th, 2022 6:00am EDT

Ending: Sep 8th, 2022 7:00am EDT

Immediately Accepting Bids
PSS (Pre 2023)
Global Online Auction Featuring Quality Biotech and Pharmaceutical Lab Equipment From Multiple Global Sellers! Multiple Locations, US.

Starting: Aug 18th, 2022 7:00am PDT

Ending: Aug 19th, 2022 8:00am PDT

Immediately Accepting Bids
OncoMyx
Global Online Auction Featuring Late Model R&D Lab Equipment From An Oncolytic ImmunoTherapies Developer! Phoenix, AZ.

Starting: Aug 15th, 2022 7:00am PDT

Ending: Aug 16th, 2022 10:00am PDT

Immediately Accepting Bids
Testing Lab
Unprecedented Offering! Online Auction Featuring State of the Art Analytical Lab & Testing Equipment! Multiple Locations, US.

Starting: Aug 9th, 2022 7:00am EDT

Ending: Aug 10th, 2022 10:00am EDT

Immediately Accepting Bids
Biosurplus
Global Online Auction Featuring Quality Surplus Biotech & Pharma Lab Equipment! San Diego, CA.

Starting: Aug 4th, 2022 7:00am PDT

Ending: Aug 5th, 2022 10:00am PDT

Immediately Accepting Bids
UK Testing Lab
Online Auction Featuring State of the Art Analytical Lab & Testing Equipment! Manchester, UK

Starting: Aug 1st, 2022 12:00pm BST

Ending: Aug 3rd, 2022 2:00am BST

Immediately Accepting Bids
PSS (Pre 2023)
Global Online Auction Featuring Quality Biotech and Pharmaceutical Lab Equipment From Multiple Global Sellers! Multiple Locations, US.

Starting: Jul 27th, 2022 7:00am PDT

Ending: Jul 28th, 2022 7:00am PDT

Immediately Accepting Bids

Managing surplus lab or regulated manufacturing assets?

Buyer FAQs

Many cleanroom components, HVAC systems, and lab assets can be reused in non-GMP or pilot-scale applications with modification.
Buyers should evaluate service history, manufacturer support status, software compatibility, and calibration requirements.
Validation documentation may be available when provided by the seller and is disclosed within the listing of assets for sale.

Seller FAQs

Sales are often structured to align with internal QA, EHS, and compliance teams prior to equipment release.
Yes. Asset-only dispositions can be structured without referencing product names or research outcomes.

Sales are often driven by pipeline changes, site consolidations, regulatory strategy shifts, or the retirement of specific research or production programs.